The Commonwealth in Limbo: How Virginia Built a Cannabis Market for Everyone Except Cannabis Companies
Five years after becoming the first Southern state to legalize, Virginia still has no legal way to buy weed. On May 19, 2026, Gov. Abigail Spanberger — who campaigned on signing exactly this bill — became the third Virginia governor in a row to veto retail cannabis, this time against her own party's trifecta. The story runs through Total Wine's hemp-THC lobby, an FBI raid on Sen. Louise Lucas's dispensary, $700M in forgone tax revenue bleeding to Maryland, and a regulator built to regulate nothing. The earliest plausible adult-use retail launch in Virginia is now 2028.
From Congo Square to Cinema Village: The Quiet Triumph of Cannabis! A Viper Vaudeville
Baba Israel and Grace Galu have spent four years turning Martin A. Lee's Smoke Signals into a touring music-theater piece that puts Black cultural authorship at the center of the cannabis story. In April it played a sold-out preview at Nublu; in May the accompanying documentary opened at Cinema Village. The most interesting cultural artifact of the legalization era isn't on a dispensary shelf — it's on stage.
Green Thumb Is Paying $70 Million a Year to License Its Own Brands
Green Thumb's Q1 looks clean by cannabis standards: $300M revenue up 7.4% YoY, $76M operating cash flow, $54.6M net cash, an aggressive buyback. But starting Q2, GTI begins paying $70 million a year in fixed brand-licensing fees to RYTHM, Inc. — a separately Nasdaq-listed holding company chaired by GTI's own CEO. The $15.4M net income was flattered by a $17M Ascend arbitration win and $6.5M RYTHM equity income; strip those out and operating income actually declined year-over-year. The DEA registration filing, the Texas TCUP license, and the dual-entity architecture all telegraph one thing: Green Thumb is engineering itself into something that isn't quite a cannabis operator anymore.
The White House's Cannabis Contradiction: Rescheduling with One Hand, Criminalizing with the Other
On May 4, ONDCP released the 2026 National Drug Control Strategy — and lumped state-legal marijuana alongside fentanyl and gas station heroin, eleven days after DOJ moved medical cannabis to Schedule III. The contradiction is statutory, but it lands hard on hemp-derived THC operators staring down a November deadline and adult-use companies awaiting the June 29 DEA hearing.
The $99 Million Line Item Curaleaf Doesn't Want You to Overthink
Curaleaf's $70M Q1 profit was a 280E reversal in disguise — strip out the $98.7M one-time tax benefit and pre-tax operating losses actually widened 74% year-over-year. The headline beat masks compressing margins, a 1.3% FCF margin, and an 11.5% bond coupon. The real story is structural: a BDO auditor swap, DEA registration filings, the completed Four 20 Pharma consolidation, and a quiet domestic wholesale pivot. Curaleaf is methodically rebuilding its infrastructure for a major-exchange uplisting.
The road to Schedule III
Tracking every step of the federal rescheduling process — from Biden's 2022 review order through Trump's executive action and the April 23 DOJ order moving medical cannabis to Schedule III, to the June 29 Phase Two hearing on full rescheduling.
Six a.m. Eastern. Before the market opens.
One email. The night's moves, the morning's agenda, and three things every operator needs to know before 9:30.